Anti-Cancer Drug Prices Fall, But Patients In Smaller Cities May Still Pay More. Here's Why

While government price caps have significantly reduced the cost of anti-cancer drugs in India, patients in smaller towns still face high costs due to travel requirements. Many patients must travel to major cities to access treatment, adding logistical and financial burdens.
Why it matters
It illustrates the gap between policy-driven price reductions and the practical realities of healthcare accessibility in developing regions.
Cancer treatment is becoming cheaper. But for thousands of patients living in smaller towns, the biggest expense may not end with the medicine's price tag. It could be the journey to find it.From November 9, the maximum retail prices (MRPs) of 543 anti-cancer medicine brands came down following a government intervention to curb excessive trade margins. The National Pharmaceutical Pricing Authority (NPPA) expects the broader exercise to save patients around Rs 2,500 crore annually.Some reductions are dramatic. A 100 mg vial of Samtepa, for instance, will cost Rs 7,150.33 instead of Rs 80,071.86. That is a reduction of nearly 91 per cent.For families paying for cancer treatment from their own savings, such cuts can make a meaningful difference.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in